Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director · 10% owner | December 03, 2024 | December 03, 2024 |
| Aspira Women's Health Inc.AWHL · Entity 7871 | 10% owner | June 05, 2026 | June 09, 2026 |
| BIODESIX INCBDSX · Entity 6053 | 10% owner · Emeritus Director | August 12, 2026 | August 13, 2026 |
| BIOLASE, INCBIOL · Entity 11470 | 10% owner | February 11, 2020 | May 15, 2020 |
| Neos Therapeutics, Inc.NEOS · Entity 141061 | 10% owner | February 17, 2017 | February 17, 2017 |
| QUIDEL CORP /DE/QDEL · Entity 126712 | Director · 10% owner | May 14, 2020 | May 18, 2020 |
| STERICYCLE INCSRCL · Entity 80873 | Director | April 30, 2018 | May 02, 2018 |
| YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195 | 10% owner | December 20, 2023 | May 17, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date December 03, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 8,310,388 |
Reported balance
After 2024-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-03 · Sale · Disposed 200,000 · Balance 8,310,388 F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. |
| Common StockSEC Table I · non-derivative | Direct | 20,225 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,225 |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 5,497 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 5,497 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold by the reporting person to John Patience, a member of the issuer's board of directors, in a private transaction for tax planning purposes.
F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Aspira Women's Health Inc.
Report date June 05, 2026 · Filed June 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 4,046,051 |
Reported balance
After 2026-06-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-05 · Purchase · Acquired 222,222 · Balance 4,046,051 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2029-06-05 | IndirectBy Jack W. Schuler Living Trust | 300,000 |
Reported balance
After 2026-06-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-05 · Purchase · Acquired 300,000 · Balance 300,000 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.75 · Expires 2030-09-17 | IndirectBy Jack W. Schuler Living Trust | 833,333 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 833,333 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.25 · Expires 2030-03-12 | IndirectBy Jack W. Schuler Living Trust | 1,801,265 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 1,801,265 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-07-26 | IndirectBy Jack W. Schuler Living Trust | 28,500 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 28,500 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.13 · Expires 2029-01-26 | IndirectBy Jack W. Schuler Living Trust | 8,888 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 8,888 F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust. |
| Common StockSEC Table I · non-derivative | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 6,536 |
| Warrant (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2027-07-09 | Direct | 6,536 |
Reported balance
Holding disclosure · report date 2026-06-05 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 6,536 |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust") and in such capacity may be deemed to beneficially own the securities held by the Living Trust.
BIODESIX INC
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 555,810 |
Reported balance
After 2026-08-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-12 · Purchase · Acquired 15,000 · Balance 555,810 F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler 2026 GRAT | 1,800,000 |
Reported balance
Holding disclosure · report date 2026-08-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,800,000 F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.00 to $24.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler 2026 GRAT.
BIOLASE, INC
Report date February 11, 2020 · Filed May 15, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 739,820 |
Reported balance
After 2020-02-11 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-02-11 · Sale · Disposed 1,307,931 · Balance 739,820 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 20,000 |
Reported balance
Holding disclosure · report date 2020-02-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,000 F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: These figures reflect a 1-for-5 reverse stock split effected by the Issuer on May 10, 2018.
F2: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust.
Neos Therapeutics, Inc.
Report date February 17, 2017 · Filed February 17, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy the Jack W Schuler Living Trust | 2,338,671 |
Reported balance
Holding disclosure · report date 2017-02-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,338,671 F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Jack W. Schuler is the sole trustee of the Jack W Schuler Living Trust. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein.
QUIDEL CORP /DE/
Report date May 14, 2020 · Filed May 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,103,249 |
Reported balance
After 2020-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-05-14 · Exercise / conversion · Acquired 2,100 · Balance 3,103,249 F1: Reflects release of restricted stock units that were previously reported on Form 4. F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-14 · Exercise / conversion · Disposed 2,100 · Balance 0 F3: Restricted stock units convert into common stock on a one-for-one basis. F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on Form 4.
F2: In addition to the shares reported on this Form 4 as directly owned by the Reporting Person, 65,000 shares are held indirectly by the Reporting Person's spouse and 1,105,263 shares are held indirectly by the Schuler Family Foundation. The Reporting Person disclaims all beneficial ownership of the shares held by his spouse and the Schuler Family Foundation, except to the extent of his pecuniary interest, if any.
F3: Restricted stock units convert into common stock on a one-for-one basis.
F4: On May 14, 2019, the reporting person was granted 2,100 restricted stock units vesting on the first anniversary of the grant date.
STERICYCLE INC
Report date April 30, 2018 · Filed May 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,078 |
Reported balance
After 2018-04-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-30 · Grant · Acquired 170 · Balance 2,078 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.
YIELD10 BIOSCIENCE, INC.
Report date December 20, 2023 · Filed May 17, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 63,789 |
Reported balance
After 2023-12-20 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2023-12-20 · Sale · Disposed 36,000 · Balance 63,789 F1: This late filing is due to an inadvertent administrative error. F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split. F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: On May 2, 2024 the Issuer effected a 1-for-24 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities beneficially owned following the transaction reported herein has been adjusted and approximated to reflect the Reverse Stock Split.
F3: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
SOLENO THERAPEUTICS INC
Report date December 09, 2022 · Filed May 15, 2023
Section 16 reporting ended · disclosed 2023-05-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Jack W. Schuler Living Trust | 36,595 |
Reported balance
After 2022-12-09 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-12-09 · Sale · Disposed 10,000 · Balance 36,595 F1: This late filing is due to an inadvertent administrative error. F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust. |
Filing footnotes · ownership attribution and instrument terms
F1: This late filing is due to an inadvertent administrative error.
F2: Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust (the "Living Trust"), and in such capacity may be deemed to beneficially own the Common Stock held by the Living Trust.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 06, 2017 Filed Nov 8, 2017 15:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 100 | $19.00 | $1,900.00 |
DisclosureSEC source: 0001144204-17-057231 · tv478904_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,293,642 F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as President of the Schuler Family Foundation. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 15:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 340,864 | $18.51 | $6,309,392.64 |
DisclosureSEC source: 0001144204-17-057231 · tv478904_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 1,293,542 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $17.98 to $18.95, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as President of the Schuler Family Foundation. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 18:54 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 141 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000060 · edgardoc.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,776 Underlying: Common Stock · 141 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. Read SEC document |
| October 18, 2017 Filed Oct 20, 2017 15:02 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 45,000 | $20.14 | $906,300.00 |
DisclosureSEC source: 0001144204-17-053445 · tv477338_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 13,040,117 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.00 to $20.30, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 17, 2017 Filed Oct 19, 2017 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 13,250 | $20.29 | $268,842.50 |
DisclosureSEC source: 0001144204-17-053204 · tv477194_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,995,117 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.28 to $20.30, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 16, 2017 Filed Oct 18, 2017 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 59,922 | $20.07 | $1,202,634.54 |
DisclosureSEC source: 0001144204-17-052986 · tv477153_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,981,867 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.98 to $20.20, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 32,060 | $19.72 | $632,223.20 |
DisclosureSEC source: 0001144204-17-052797 · tv477064_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,954,005 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.45 to $20.05, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F7 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 29,240 | $18.81 | $550,004.40 |
DisclosureSEC source: 0001144204-17-052797 · tv477064_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,921,945 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.45 to $19.40, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F7 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 12, 2017 Filed Oct 16, 2017 15:06 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 276,200 | $19.74 | $5,452,188.00 |
DisclosureSEC source: 0001144204-17-052595 · tv477025_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,892,705 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $19.70 to $20.20, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 11, 2017 Filed Oct 13, 2017 10:30 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 51,600 | $20.27 | $1,045,932.00 |
DisclosureSEC source: 0001144204-17-052357 · tv476939_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,616,505 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.075 to $20.40, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:03 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherWarrants (Right to Buy) · Derivative | 773,003 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0000905148-17-000783 · form4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 773,003 shares Expires 2017-08-31 F1 · ownership.nature: These shares of common stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 21:03 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherCommon Stock, par value $0.001 | 773,003 | $1.00 | $773,003.00 |
DisclosureSEC source: 0000905148-17-000783 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,905,223 F1 · ownership.nature: These shares of common stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 20:49 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseWarrants (Right to Buy) · Derivative | 773,003 | Not disclosed Strike: $1.00 | Not disclosed |
DisclosureSEC source: 0000905148-17-000774 · form4.xml · derivative · entry 4 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 773,003 Underlying: Common Stock · 773,003 shares Expires 2017-08-31 F3 · derivative.exercise_price: To the extent that any part of this warrant is not exercised by August 31, 2017, the exercise price of the warrant will revert to $2.00 per share and the warrant will expire on December 23, 2017. F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to reduce the exercise price from $2.00 to $1.00 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new warrant. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to reduce the exercise price from $2.00 to $1.00 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new warrant. F3 · derivative.expiration_date: To the extent that any part of this warrant is not exercised by August 31, 2017, the exercise price of the warrant will revert to $2.00 per share and the warrant will expire on December 23, 2017. F1 · ownership.nature: These shares of Common Stock and Warrants to acquire Common Stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 25, 2017 Filed Aug 29, 2017 20:49 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | OtherWarrants (Right to Buy) · Derivative | 773,003 | Not disclosed Strike: $2.00 | Not disclosed |
DisclosureSEC source: 0000905148-17-000774 · form4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 773,003 shares Expires 2017-12-23 F2 · kind: The two reported transactions involved an amendment of an outstanding warrant to reduce the exercise price from $2.00 to $1.00 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new warrant. F2 · price: The two reported transactions involved an amendment of an outstanding warrant to reduce the exercise price from $2.00 to $1.00 per share. The amendment is reported above as the cancellation of the old warrant and the acquisition of a new warrant. F1 · ownership.nature: These shares of Common Stock and Warrants to acquire Common Stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 11:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 12,730 | $21.76 | $277,004.80 |
DisclosureSEC source: 0001144204-17-044690 · v473872_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,564,905 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.70 to $21.80, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F7 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 11:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 37,270 | $21.34 | $795,341.80 |
DisclosureSEC source: 0001144204-17-044690 · v473872_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,552,175 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.70 to $21.68, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F7 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 11:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 8,200 | $21.35 | $175,070.00 |
DisclosureSEC source: 0001144204-17-043789 · v473508_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,514,905 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.28 to $21.45, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 11:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 23,400 | $21.35 | $499,590.00 |
DisclosureSEC source: 0001144204-17-043620 · v473423_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,506,705 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.20 to $21.50, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 11:01 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 80,000 | $21.43 | $1,714,400.00 |
DisclosureSEC source: 0001144204-17-043378 · v473193_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,483,305 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.20 to $21.88, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F6 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:54 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 129 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000050 · edgardoc.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,635 Underlying: Common Stock · 129 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. Read SEC document |
| July 03, 2017 Filed Aug 2, 2017 20:53 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | PurchaseCommon Stock Warrants · Derivative | 185,392 | $4.00 Strike: $5.04 | $741,568.00 |
DisclosureSEC source: 0001179110-17-010978 · edgar.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 485,062 Underlying: Common Stock · 185,392 shares Expires 2024-01-07 F7 · price: In a concurrent private placement, the Issuer agreed to issue to the Investors warrants to purchase one share of common stock at an exercise price of $5.04 per share for each share of common stock purchased for $4.00 per share. The reported securities include the 160,392 warrants purchased by the Jack W. Schuler Living Trust and the 25,000 warrants purchased by Schuler Grandchildren LLC. F7 · derivative.underlying_shares: In a concurrent private placement, the Issuer agreed to issue to the Investors warrants to purchase one share of common stock at an exercise price of $5.04 per share for each share of common stock purchased for $4.00 per share. The reported securities include the 160,392 warrants purchased by the Jack W. Schuler Living Trust and the 25,000 warrants purchased by Schuler Grandchildren LLC. F8 · balance_after: The reported securities consist of 149,835 warrants held by Jack W. Schuler, 149,835 warrants held by the Schuler Family Foundation, 160,392 warrants held by the Jack W. Schuler Living trust, and 25,000 warrants held by Schuler Grandchildren LLC. F6 · ownership.nature: Mr. Schuler indirectly owns the reported securities through the Jack W. Schuler Living Trust and Schuler Grandchildren LLC. Read SEC document |
| July 03, 2017 Filed Aug 2, 2017 20:53 UTC | YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195 | PurchaseCommon Stock | 185,392 | $4.00 | $741,568.00 |
DisclosureSEC source: 0001179110-17-010978 · edgar.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,383,421 F1 · shares: The reported securities include the 160,392 shares of common stock purchased by the Jack W. Schuler Living Trust and the 25,000 shares of common stock purchased by Schuler Grandchildren LLC for $4.00 per share pursuant to a Securities Purchase Agreement, dated July 3, 2017 by and among the Issuer and certain investors named therein (the "Investors"). F1 · price: The reported securities include the 160,392 shares of common stock purchased by the Jack W. Schuler Living Trust and the 25,000 shares of common stock purchased by Schuler Grandchildren LLC for $4.00 per share pursuant to a Securities Purchase Agreement, dated July 3, 2017 by and among the Issuer and certain investors named therein (the "Investors"). F2 · balance_after: The shares of common stock reported herein give effect to the 1-for-10 reverse stock split which became effective on May 26, 2017 in accordance with the terms of the Certificate of Amendment to the Issuer's Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on May 25, 2017. F3 · balance_after: Mr. Schuler may be deemed to be a member of a "group" for purposes of Section 13(d) with his wife, Renate Schuler, the Schuler Family Foundation, and the Jack W. Schuler Living Trust but disclaims Section 13(d) beneficial ownership over the securities held by Ms. Schuler and the Schuler Family Foundation. F4 · balance_after: Mr. Schuler has sole voting and investment power over the shares issued to Schuler Grandchildren LLC and the Jack W. Schuler Living Trust. He disclaims beneficial ownership over the shares held by Schuler Grandchildren LLC and has beneficial ownership over the shares held by the Jack W. Schuler Living Trust. F5 · balance_after: The reported securities consist of 218,565 shares of common stock owned by Jack W. Schuler, 978,414 shares of common stock owned by the Schuler Family Foundation, 160,392 shares of common stock owned by the Jack W. Schuler Living Trust, and 26,050 shares of common stock owned by Schuler Grandchildren LLC (which 26,050 shares of common stock include 1,050 shares of common stock purchased on December 31, 2014). F6 · ownership.nature: Mr. Schuler indirectly owns the reported securities through the Jack W. Schuler Living Trust and Schuler Grandchildren LLC. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:43 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionRestricted Stock Units · Derivative | 495 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001692742-17-000035 · edgardoc.xml · derivative · entry 5 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 495 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:43 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionCommon Stock | 495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001692742-17-000035 · edgardoc.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 616,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:43 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 1,506 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000035 · edgardoc.xml · derivative · entry 6 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 Underlying: Common Stock · 1,506 shares Expires not disclosed F3 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. F3 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:09 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantNon-Qualified Stock Options · Derivative | 5,065 | $0.00 Strike: $24.80 | $0.00 |
DisclosureSEC source: 0001209191-17-033753 · doc4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,065 Underlying: Common Stock · 5,065 shares Expires 2027-05-16 Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:09 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Equity Grant) · Derivative | 2,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033753 · doc4.xml · derivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,016 Underlying: Common Stock · 2,016 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F3 · derivative.exercise_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. F3 · derivative.expiration_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. Read SEC document |
| May 16, 2017 Filed May 18, 2017 20:09 UTC | QUIDEL CORP /DE/ QDEL · Entity 126712 | GrantRestricted Stock Units (Premium) · Derivative | 485 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-033753 · doc4.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 485 Underlying: Common Stock · 485 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Quidel Corporation common stock. F2 · shares: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F2 · derivative.exercise_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.exercise_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. F2 · derivative.expiration_date: The restricted stock units were received in lieu of cash payments to the reporting person for certain retainer and Board of Director service-related fees under a 2017 compensation program applicable to participating non-employee directors. Vested restricted stock units may be deferred, in which case, payment will occur according to the elected deferral schedule. F3 · derivative.expiration_date: The restricted stock units vest on the first anniversary date of the grant date, May 16, 2018. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 19:11 UTC | Accelerate Diagnostics, Inc AXDX] · Entity 78156 | GrantStock Option (right to buy) · Derivative | 11,721 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0001144204-17-018994 · v463577_4.xml · derivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,721 Underlying: Common Stock · 11,721 shares Expires 2027-04-01 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2017. F2 · balance_after: The total number of stock options held by the reporting person was previously aggregated in Table II of the reporting person's previous Form 4s. The number of stock options reported on this Form 4 reflects only the number of stock options of the class reported herein. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:19 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseWarrants (Right to buy) · Derivative | 730,560 | $0.13 Strike: $1.80 | $91,320.00 |
DisclosureSEC source: 0000905148-17-000362 · form4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 730,560 Underlying: Common Stock · 730,560 shares Expires 2022-02-17 F1 · ownership.nature: These shares of common stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| February 13, 2017 Filed Feb 15, 2017 22:19 UTC | Aspira Women's Health Inc. VRML · Entity 7871 | PurchaseCommon Stock, par value $0.001 | 974,081 | $1.40 | $1,363,713.40 |
DisclosureSEC source: 0000905148-17-000362 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 3,132,220 F1 · ownership.nature: These shares of common stock are directly owned by the Jack W. Schuler Living Trust. Jack W. Schuler is the sole trustee of the Jack W. Schuler Living Trust. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 19:32 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 128,368 | $19.00 | $2,438,992.00 |
DisclosureSEC source: 0001144204-17-001697 · v456705_4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Schuler Family Foundation Disclosed balance after: 952,678 F2 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as President of the Schuler Family Foundation. F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 19:32 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 211,000 | $19.00 | $4,009,000.00 |
DisclosureSEC source: 0001144204-17-001697 · v456705_4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Jack W. Schuler Living Trust Disclosed balance after: 12,403,305 F1 · ownership.nature: Mr. Schuler has sole voting and dispositive power with respect to such shares in his capacity as trustee of the Jack W. Schuler Living Trust. F5 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 04, 2017 Filed Jul 13, 2017 17:10 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 24,255 | $1.52 | $36,942.79 |
DisclosureSEC source: 0000905148-17-000667 · form4.xml · nonDerivative · entry 4 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,238,756 F5 · price: This price reflects the weighted average purchase price for open-market purchases of shares of Shares made by the Reporting Persons on January 4, 2017, within a $1.00 range. The actual prices for these transactions range from $1.50 to $1.53, inclusive. F1 · ownership.nature: These shares of Common Stock ("Shares") are held by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. Read SEC document |
| January 03, 2017 Filed Jul 13, 2017 17:10 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 9,100 | $1.44 | $13,145.86 |
DisclosureSEC source: 0000905148-17-000667 · form4.xml · nonDerivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,214,501 F4 · price: This price reflects the weighted average purchase price for open-market purchases of shares of Shares made by the Reporting Persons on January 3, 2017, within a $1.00 range. The actual prices for these transactions range from $1.425 to $1.46, inclusive. F1 · ownership.nature: These shares of Common Stock ("Shares") are held by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. Read SEC document |
| December 30, 2016 Filed Jul 13, 2017 17:10 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 8,002 | $1.39 | $11,124.38 |
DisclosureSEC source: 0000905148-17-000667 · form4.xml · nonDerivative · entry 2 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,205,401 F3 · price: This price reflects the weighted average purchase price for open-market purchases of shares of Shares made by the Reporting Persons on December 30, 2016, within a $1.00 range. The actual prices for these transactions range from $1.39 to $1.40, inclusive. F1 · ownership.nature: These shares of Common Stock ("Shares") are held by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. Read SEC document |
| December 29, 2016 Filed Jul 13, 2017 17:10 UTC | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 2,200 | $1.41 | $3,096.06 |
DisclosureSEC source: 0000905148-17-000667 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,197,399 F2 · price: This price reflects the weighted average purchase price for open-market purchases of shares of Shares made by the Reporting Persons on December 29, 2016, within a $1.00 range. The actual prices for these transactions range from $1.395 to $1.42, inclusive. The Reporting Persons further undertake to provide upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3), (4), and (5) to this Form 4. F1 · ownership.nature: These shares of Common Stock ("Shares") are held by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. Read SEC document |
| December 14, 2016 Filed Dec 21, 2016 17:16 UTC | STERICYCLE INC SRCL · Entity 80873 | GiftCommon Stock | 2,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001568150-16-000147 · edgardoc.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 615,647 Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:38 UTC | BIOLASE, INC BIOL · Entity 11470 | ConversionSeries C Participating Convertible Preferred Stock · Derivative | 36,991 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0000905148-16-001919 · form4.xml · derivative · entry 3 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 3,699,100 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: These shares of Series C Participating Convertible Preferred Stock ("Preferred Stock") were acquired by the Trust in a privately negotiated transaction with the Issuer, which closed on August 8, 2016. F5 · derivative.expiration_date: The Preferred Stock had no expiration date. F6 · ownership.nature: The Preferred Stock was held directly by the Trust. Mr. Schuler serves as sole trustee to the Trust. F7 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the Preferred Stock except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person was the beneficial owner of the Preferred Stock for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 30, 2016 Filed Oct 4, 2016 17:38 UTC | BIOLASE, INC BIOL · Entity 11470 | ConversionCommon Stock | 3,699,100 | $1.13 | $4,179,983.00 |
DisclosureSEC source: 0000905148-16-001919 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,195,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 30, 2016, as a result of receipt of the Requisite Stockholder Approval (defined and described further in the Securities Purchase Agreement dated August 1, 2016 and filed as Exhibit 99.1 to the Current Report on Form 8-K filed by the Issuer on August 2, 2016), each share of Preferred Stock (as defined below) automatically converted into 100 shares of Common Stock, reflecting a conversion price equal to $1.13 per share. F8 · balance_after: This figure has been reduced by 51,438 shares of Common Stock that had been inadvertently included in the shares of Common Stock beneficially owned by the Trust in Mr. Schuler's prior Form 4 filings. F2 · ownership.nature: The Common Stock is held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. F3 · ownership.nature: Each Reporting Person disclaims beneficial ownership of the Common Stock except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the Common Stock for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| October 21, 2015 Filed Oct 7, 2016 12:51 UTC Amendment | BIOLASE, INC BIOL · Entity 11470 | PurchaseCommon Stock | 33,762 | $0.95 | $32,073.90 |
DisclosureSEC source: 0000905148-16-001934 · form4.xml · nonDerivative · entry 1 SCHULER JACK W · CIK 0001021412 · 10% owner Jack W. Schuler Living Trust · CIK 0001661351 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 4,213,429 F1 · shares: These shares of Common Stock were inadvertently omitted from the reporting person's Form 4 filed December 18, 2015, and also were omitted from the reporting person's total amount of securities beneficially owned as reported in subsequent Forms 4, until corrected in the Form 4 filed October 4, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares of Common Stock were purchased in multiple transactions at prices within a $1.00 range. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price for each transaction reported in this Form 4. F3 · ownership.nature: These shares of Common Stock are held directly by the Jack W. Schuler Living Trust (the "Trust"). Mr. Schuler serves as sole trustee to the Trust. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.